VS 367
Alternative Names: VS-367Latest Information Update: 05 Mar 2024
At a glance
- Originator Vasa Therapeutics
- Class Obesity therapies; Peptides; Urologics; Vascular disorder therapies
- Mechanism of Action Apelin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity; Peripheral arterial disorders; Renal failure
Most Recent Events
- 26 Feb 2024 Preclinical clinical trials in Renal failure in USA (parenteral) (Vasa Therapeutics pipeline, February 2024)
- 26 Feb 2024 Preclinical trials in Obesity (Combination therapy) in USA (parenteral) (Vasa Therapeutics pipeline, February 2024)
- 26 Feb 2024 Preclinical trials in Peripheral arterial disorders in USA (parenteral) (Vasa Therapeutics pipeline, February 2024)